NCT04112472

Brief Summary

The primary objective of this clinical trial is to assess the clinical performance of the investigational device. To that end, the Limits of Agreement with respect to comparator devices are analyzed. The Limits of Agreement allow estimating the expected measurement deviation per measurand, which is compared to the "maximum acceptable measurement error", as defined by the Risk Analysis of the investigational device, to assess the risk involved in measurements of the investigational device. Furthermore, the in-vivo repeatability will be quantified for each measurand, as well as the confidence intervals for mean deviation with respect to the current gold standard device. As a secondary objective of the study, raw measurement data will be collected to allow for improvement of existing algorithms, development of additional measurands and for retrospective analysis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 11, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

September 20, 2019

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 2, 2019

Completed
Last Updated

March 30, 2026

Status Verified

March 1, 2026

Enrollment Period

2 months

First QC Date

September 20, 2019

Last Update Submit

March 25, 2026

Conditions

Outcome Measures

Primary Outcomes (24)

  • Keratometry Measurand: Kmean (Spherical refractive power of central cornea) in keratometric diopters [dpt]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for Kmean.

    Through study completion, approximately 7 months.

  • Keratometry Measurand: AST (Anterior central corneal astigmatism) in [dpt]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for AST.

    Through study completion, approximately 7 months.

  • Keratometry Measurand: Axis (Anterior steep meridian angle) in [°]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for Axis. Axis is the angle of the anterior central corneal astigmatism. The value of Axis is measured in \[°\], whereas the differences shall be expressed in \[dpt\].

    Through study completion, approximately 7 months.

  • Axial Measurand: AL (Axial length) in [mm]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for AL. AL is measured from the corneal tear film to the inner limiting membrane.

    Through study completion, approximately 7 months.

  • Axial Measurand: CCT (Corneal thickness) in [μm]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for CCT. CCT is measured from the corneal tear film to the corneal endothelium.

    Through study completion, approximately 7 months.

  • Axial Measurand: ACD (Anterior chamber depth) in [mm]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for ACD. ACD is measured from the corneal tear film to the anterior surface of the lens.

    Through study completion, approximately 7 months.

  • Axial Measurand: LT (Lens thickness) in [mm]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for LT. LT is measured from the anterior to the posterior surface of the lens.

    Through study completion, approximately 7 months.

  • Imaging Measurand: WTW (White-to-White) in [mm]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator devices for WTW. WTW distance is the horizontal diameter of a best fit circle to the iris border.

    Through study completion, approximately 7 months.

  • Imaging Measurand: ICX / ICY (Iris barycenter in horizontal direction / in vertical direction) in [mm]

    In-vivo repeatability of investigational and comparator device for Iris barycenter. The iris barycenter is the displacement of the iris center relative to the vertex in X (horizontal direction) and Y (vertical direction) coordinates.

    Through study completion, approximately 7 months.

  • Imaging Measurand: PD (Pupil diameter) in [mm]

    In-vivo repeatability of investigational and comparator device for PD. PD is measured at the diameter of a best fit circle to the pupil border.

    Through study completion, approximately 7 months.

  • Imaging Measurand: PCX / PCY (Pupil barycenter in horizontal direction / in vertical direction) in [mm]

    In-vivo repeatability of investigational and comparator device for Iris barycenter. The pupil barycenter is the displacement of the iris center relative to the vertex in X (horizontal direction) and Y (vertical direction) coordinates.

    Through study completion, approximately 7 months.

  • Anterior corneal topography: Elevation (Anterior torical elevation) in [µm] (2D-map)

    In-vivo repeatability and confidence interval of mean deviation with respect to comparator device, for elevation in \[µ\]; axial curvature in \[dpt\].

    Through study completion, approximately 7 months.

  • Anterior corneal topography: Axial curvature (Anterior tangential curvature) in [dpt] (2D-map)

    In-vivo repeatability and confidence interval of difference between investigational and comparator devices for Anterior torical elevation. The measuring performance over the 2D-map is subdivided in three zones (central zone, middle zone, peripheral zone).

    Through study completion, approximately 7 months.

  • Posterior corneal topography: Elevation (Posterior torical elevation) in [µm] (2D-map)

    In-vivo repeatability of investigational and comparator device for Posterior torical elevation. The measuring performance over the 2D-map is subdivided in three zones (central zone, middle zone, peripheral zone).

    Through study completion, approximately 7 months.

  • Posterior corneal topography: Axial curvature (Posterior tangential curvature) in [dpt] (2D-map)

    In-vivo repeatability and confidence interval of differences of investigational and comparator devices for Posterior tangential curvature. The measuring performance over the 2D-map is subdivided in three zones (central zone, middle zone, peripheral zone).

    Through study completion, approximately 7 months.

  • Corneal pachymetry: Corneal thickness map in [µm]

    In-vivo repeatability and confidence interval of differences of investigational and comparator device for Corneal thickness map. The measuring performance over the 2D-map is subdivided in three zones (central zone, middle zone, peripheral zone).

    Through study completion, approximately 7 months.

  • Simulated Keratometry: SimKmean (Mean simulated keratometry) in [dpt]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator devices for SimKmean.

    Through study completion, approximately 7 months.

  • Simulated Keratometry: SimAST (Simulated astigmatism) in [dpt]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator devices for SimAST.

    Through study completion, approximately 7 months.

  • Simulated Keratometry: SimAxis (Simulated keratometry anterior steep meridian angle) in [°]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for SimAxis. The value of Axis is measured in \[°\], whereas the differences shall be expressed in \[dpt\]. SimAxis is the angle of the larger simulated keratometry radius with respect to the horizontal axis X.

    Through study completion, approximately 7 months.

  • Simulated Keratometry: Anterior corneal shape factor (E): Dimensionless quantity

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for Anterior corneal shape factor (E), that characterizes the anterior corneal asphericity.

    Through study completion, approximately 7 months.

  • Simulated Posterior Keratometry: SimPKmean (Mean simulated posterior keratometry) in [dpt]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for SimPKmean. SimPKmean is the corresponding refractive power in diopters.

    Through study completion, approximately 7 months.

  • Simulated Posterior Keratometry: SimPAST (Simulated keratometry posterior corneal astigmatism) in [dpt]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for SimPAST.

    Through study completion, approximately 7 months.

  • Simulated Posterior Keratometry: SimPAxis (Simulated keratometry posterior steep meridian angle) in [°]

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for SimPAxis. SimPAxis represents the angle of the larger simulated keratometry radius of curvature with respect to the horizontal axis X.

    Through study completion, approximately 7 months.

  • Simulated Posterior Keratometry: Posterior corneal shape factor (PE): Dimensionless quantity

    In-vivo repeatability, limits of agreement and confidence interval of difference between investigational and comparator device for Posterior corneal shape factor (PE), that characterizes the posterior corneal asphericity.

    Through study completion, approximately 7 months.

Other Outcomes (2)

  • Acquisition of volumetric OCT Data of the eye.

    Through study completion, approximately 7 months

  • Acquisition of photographic images of the eye.

    Through study completion, approximately 7 months

Study Arms (1)

Examination of participants

EXPERIMENTAL

Examination of participants by means of the investigational device as well as the comparative devices.

Device: EYESTAR 900

Interventions

EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.

Examination of participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • volunteers with normal phakic eye;
  • patients seeking cataract surgery;
  • patients with pseudophakic eye;
  • patients with oil-filled eye;
  • patients with aphakic eye.

You may not qualify if:

  • underage patients (younger than 18 years);
  • vulnerable patients;
  • inability to give informed consent;
  • inability to maintain stable fixation;
  • corneal lesions or scarring;
  • previous corneal surgery (except: pseudophakic eyes, oil-filled eyes, aphakic eyes);
  • previous intraocular surgery (except: pseudophakic eyes, oil-filled eyes, aphakic eyes);
  • active inflammation of the eye;
  • active infection of the eye;
  • tear film break up time of less than 5 sec.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hopital Basel

Basel, 4056, Switzerland

Location

Study Officials

  • David Goldblum, Prof. Dr.

    University Hospital, Basel, Switzerland

    PRINCIPAL INVESTIGATOR
  • Julian Kool van Langenberghe, ing.

    Haag-Streit AG

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 20, 2019

First Posted

October 2, 2019

Study Start

July 11, 2019

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

March 30, 2026

Record last verified: 2026-03

Locations